At ASCO, researchers reported that more patients who switched to camizestrant at molecular progression had total ctDNA ...
AstraZeneca Plc AZN on Tuesday reported updated Phase 3 SERENA-6 trial results showing that camizestrant combined with a CDK4 ...
AstraZeneca's camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) has been ...
Further positive results from the Phase III SERENA-6 trial showed AstraZeneca's camizestrant plus a cyclin-dependent kinase (CDK) 4/6 inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results